[BLRX] BioLineRx Ltd.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 46.83 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.98 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart BLRX

Refresh chart

Strongest Trends Summary For BLRX

BLRX is in the medium-term down -15% below S&P in 2 months and down -65% below S&P in 8 months. In the long-term down -67% below S&P in 2 years and down -96% below S&P in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: BioLineRx Ltd., a clinical stage biopharmaceutical development company, is engaged in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company?s development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a resorbable polymer solution being developed to reduce or prevent the ventricular remodeling; BL-8040, a peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a polymer for the treatment of celiac disease; BL-5010, which is being developed as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the Hepatitis C virus and other viral indications. It also has three therapeutic candidates in the preclinical stages of development, such as BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies/asthma; a

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding56.42 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV0.39 Price/Cash Per Share
Price/Free Cash Flow-3.12 ROA-10.2% ROE-13.77% ROI
Current Ratio3.57 Quick Ratio Long Term Debt/Equity Debt Ratio0.35
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities25.78 M Cash From Operating Activities8.14 M Gross Profit
Net Profit-22.31 M Operating Profit Total Assets159.17 M Total Current Assets147.05 M
Total Current Liabilities41.23 M Total Debt Total Liabilities41.23 M Total Revenue
Technical Data
High 52 week1.45 Low 52 week0.36 Last close0.39 Last change5.45%
RSI32.29 Average true range0.02 Beta0.64 Volume46.18 K
Simple moving average 20 days-3.71% Simple moving average 50 days-7.01% Simple moving average 200 days-44.77%
Performance Data
Performance Week1.42% Performance Month-10.26% Performance Quart-38.21% Performance Half-53.58%
Performance Year-55.25% Performance Year-to-date-11.96% Volatility daily2.06% Volatility weekly4.6%
Volatility monthly9.43% Volatility yearly32.68% Relative Volume117.29% Average Volume1.48 M
New High New Low

News

2019-05-17 09:00:01 | BioLineRx BLRX Moves to Buy: Rationale Behind the Upgrade

2019-05-14 07:00:00 | BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-07 08:00:00 | BioLineRx to Report First Quarter 2019 Results on May 14, 2019

2019-05-07 07:00:00 | BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors

2019-05-01 08:10:00 | Biotech News, What Milestones and Catalysts Could Drive BioLineRx Shares in 2019

2019-03-28 07:00:00 | BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update

2019-03-27 15:00:00 | Four Tech Stocks Sparking Activity on Wednesday

2019-03-27 07:00:00 | BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients

2019-03-21 08:00:00 | BioLineRx to Report Annual 2018 Results on March 28, 2019

2019-03-14 07:00:00 | BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference

2019-02-07 13:42:00 | BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

2019-02-05 11:40:00 | BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

2019-02-05 10:30:00 | Biotech on the Brink of Breaking Out

2019-02-05 07:47:21 | The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

2019-02-04 17:54:00 | BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and Warrants

2019-02-04 09:30:00 | Watch These 4 Healthcare Stocks Set The Pace On Monday 2/4/19

2019-02-04 07:00:00 | BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer

2019-01-02 09:00:00 | BioLineRx to Present at the 2019 Biotech Showcase

2018-12-11 07:00:00 | BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration

2018-12-06 07:00:00 | BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York

2018-11-20 08:45:00 | New Healthcare Trends Have Investors Looking at 4 Stocks

2018-11-20 07:00:00 | BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134

2018-11-16 08:10:00 | Recent Analysis Shows BioLineRx, Interlink Electronics, IMV INC, PAR Technology, Hudson Global, and Identiv Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-08 07:00:00 | BioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial Update

2018-11-01 08:00:00 | BioLineRx to Report Third Quarter 2018 Results on November 8, 2018

2018-10-20 13:00:00 | BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress

2018-10-19 07:00:00 | BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress

2018-10-17 08:10:00 | BioLineRx, High Potential Near Term Catalysts, Analysts Review and Target

2018-10-08 10:48:02 | Can The Uptrend Continue for BioLineRx BLRX?

2018-10-05 08:56:12 | BioLineRx BLRX in Focus: Stock Moves 7.5% Higher

2018-10-04 16:06:08 | BioLineRx Stock Up on Stake Increase in Lead Cancer Program

2018-10-04 08:00:00 | Today's Research Reports on Trending Tickers: BioLineRx and OPKO Health

2018-10-03 06:00:00 | BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications

2018-09-26 11:14:03 | Portola's PTLA Lymphoma Candidate Gets Orphan Drug Status

2018-09-21 11:19:03 | BioLineRx BLRX Continue to Surge Higher?

2018-08-30 07:00:00 | BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York

2018-08-13 08:00:00 | Bioline RX Ltd Sponsored ADR to Host Earnings Call

2018-08-13 07:00:00 | BioLineRx Reports Second Quarter 2018 Financial Results

2018-08-07 07:00:00 | BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization

2018-08-06 06:36:00 | BioLineRx to Report Second Quarter 2018 Results on August 13, 2018

2018-08-01 07:00:00 | BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

2018-07-30 09:05:47 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-30 07:00:00 | BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer

2018-07-19 11:14:03 | CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

2018-07-10 09:58:01 | Aclaris' Alopecia Candidate Gets Fast Track Designation

2018-07-08 19:16:35 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

2018-07-06 10:34:02 | Aclaris Stock Up on JAK Inhibitor's Encouraging Activity

2018-06-29 07:06:11 | BioLineRx Sees Hammer Chart Pattern: Time to Buy?

2018-06-22 09:56:01 | Shire SHPG HAE Drug Gets FDA Nod for Pediatric Population

2018-06-18 07:00:00 | BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients